研究実績

Mino T et al. (R)-WAC-224, a novel anticancer quinolone, confers promising activities against acute myeloid leukemia. Invest New Drugs. 2023 Oct;41(5):751-760.

Mengistu L et al. Lcn2 mediates adipocyte-muscle-tumor communication and hypothermia in pancreatic cancer cachexia. Mol Metab. 2022 Dec:66:101612.

Ricciardiello F et al. Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature—A New Goal for Early Diagnosis and Therapy? J. Clin. Med. 2021, 10, 2019.

Takashima M et al. Localized and systemic inflammatory mediators in a murine acute mastitis model. Journal of Inflammation Research 2021:14 4053–4067.

Kawasaki H and Amano H Anti-inflammatory role of microRNA-429 in human gingival epithelial cells – inhibition of IL-8 production through direct binding to IKKβ mRNA. MOLECULAR MEDICINE REPORTS 24: 581, 202

Okazaki Y et al. Increased glucose metabolism in Arid5b -/- skeletal muscle is associated with the down-regulation of TBC1 domain family member 1 (TBC1D1) Biol Res. 2020 Oct 6; 53(1):45.

Michele C et al. Definition of miRNA Signatures of Nodal Metastasis in Lca: miR-449a Targets Notch Genes and Suppresses Cell Migration and Invasion Mol Ther Nucleic Acids 2020 June 5; 20:711-724.

Michele C et al. Insight Toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact Int J Mol Sci. 2020 May; 21(10): 3693.

Misso G et al. miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. Mol Ther Nucleic Acids. 2019 Mar 13; 16:391-406.

Caraglia M, Misso G et al. Non-coding RNAs as a new dawn in tumor diagnosis. Semin Cell Dev Biol. 2018 Jun; 78:37-50.

Caraglia M et al. Determination of miRNAs from Cancer Stem Cells Using a Low Density Array Platform. Methods Mol Biol. 2018 1692:149-156.

Hirano T et al. Discovery of a Novel Fluoroquinolone Antibiotic Candidate WFQ-228 with Potent Antimicrobial Activity and the Potential to Overcome Major Drug Resistance. Chem Pharam Bull. 2018; 1.66(3):235-238.

Grassia V et al. Salivary microRNAs as new molecular markers in cleft lip and palate: a new frontier in molecular medicine. Oncotarget. 2018 Apr 10; 9(27):18929-18938.

Itoh K et al. Discovery of WQ-3810: Design, Synthesis, and Evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoroquinolones as Orally Active Antibacterial Agent . Eur J Med Chem. 2015 Oct 20;103:354-60.

Sakata K et al. Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β.Biochem Biophys Res Commun. 2014 Jan 17;443(3):950-6.

Tanaka K et al. A Novel Acylaminoimidazole Derivative, WN1316, Alleviates Disease Progression via Suppression of Glial Inflammation in ALS Mouse Model. Plos ONE. 2014 January 31; 9: e87728.

Zhanel GG et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014 Jan;74(1):31-51.

Doig P et al. Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping. Bioorg Med Chem. 2014 Nov 1;22(21):6256-69.

Kazamori D et al. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens. Int J Antimicrob Agents. 2014 Nov;44(5):443-9.

Yoneshiro T et al. Impact of UCP1 and b3AR gene polymorphisms on age-related changes in brown adipose tissue and adiposity in humans. Int J Obes (Lond). 2013 Jul;37(7):993-8.

Sakata K et al. HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor. Sci Rep. 2013 Nov 22;3:3243.

Kitaoka S et al. FGT-1 Is a Mammalian GLUT2-Like Facilitative Glucose Transporter in Caenorhabditis elegans Whose Malfunction Induces Fat Accumulation in Intestinal Cells. PLoS ONE. 2013; 8(6): e68475.

Asano T et al. Identification, Synthesis, and Biological Evaluation of 6-[(6R)-2-(4-Fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a Potent p38 MAP Kinase Inhibitor. J. Med. Chem. 2012; 55 (17): 7772-85.

Miyata J et al. Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5681-4.

Takahashi R et al. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J Biochem. 2010 Jan;147(1):95-107.

木下智彦. 新しい肥満治療薬への期待:DGAT‐1選択的阻害剤. ファルマシア. 2009; 45(1): 69-70.

Hikami K et al. Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem Biophys Res Commun. 2008; 373(3): 403-7.

Toda A et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett. 2008;18(17): 4849-52.

Murano K et al. Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure. Bioorg Med Chem. 2008 Mar 1;16(5):2261-75.

高橋亮ほか. NMPRTase/PBEF/Visfatin:ホスホリボシル転移酵素の触媒機構と多機能性. 日本応用酵素協会誌. 2008;42:11-21.

Takahashi R et al. Crystallization of human nicotinamide phosphoribosyltransferase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 May 1;63(5):375-7.

倉本康弘. 湧永製薬におけるニューキノロン系抗菌剤の創薬研究. MEDCHEM NEWS. 2007; 17(2 ) .

Takeda S et al. Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007 Nov;30(5):443-5.

Oomizu S et al. Fucoidan prevents C epsilon germline transcription and NFkappaB p52 translocation for IgE production in B cells. Biochem Biophys Res Commun. 2006; 350(3): 501-7.

Tanaka et al. Semi-purification of the immunoglobulin E-sweat antigen acting on mast cells and basophils in atopic dermatitis. Exp Dermatol. 2006;15(4):283-90.

Oomizu et al. Oral administration of pulverized Konjac glucomannan prevents the increase of plasma IgE and IgG levels induced by the injection of syngeneic keratinocyte extracts in BALB/c mice. Clinical and Experimental Allergy. 2006; 36(1):102-110.

赤松久. 疎水性相互作用で基質を保持する固相合成. ファルマシア. 2006; 42(5): 471-472.

Inokuma K et al. Indispensable role of mitochondrial UCP1 for antiobesity effect of beta3-adrenergic stimulation. Am J Physiol Endocrinol Metab. 2006 May;290(5):E1014-21.

Wang Y et al. Potential contribution of vasoconstriction to suppression of heat loss and homeothermic regulation in UCP1-deficient mice. Pflugers Arch. 2006; 452(3): 363-9.

猪熊健一ほか. エネルギー消費における脱共役蛋白質UCP1の役割. 別冊：医学のあゆみ 糖尿病・代謝症候群. 2004-2006.　

Kontani Y et al. UCP1 deficiency increases susceptibility to diet-induced obesity with age. Aging Cell. 2005; 4(3): 147-55.

猪熊健一ほか. UCP1はβ3アドレナリン受容体アゴニストの抗肥満効果に必須である. 肥満研究.2005;11(2):188-90.

Inokuma K et al. Uncoupling protein 1 is necessary for norepinephrine-induced glucose utilization in brown adipose tissue. Diabetes. 2005;54(5):1385-91.

林則博. フルオロキノロン剤の光毒性に関する新たな構造－毒性相関と光安定性について. YAKUGAKU ZASSHI. 2005;125(3):255-261.

猪熊健一ほか. 脱共役蛋白質（UCP）によるエネルギー消費調節メカニズムとその意義. 現代医療. 2004; 36(9): 1815-20.

Hayashi N et al. New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1. Antimicrob Agents Chemother. 2004;48(3):799-803.

Akamatsu H, Fukase K. Solid-Phase Synthesis of Indol-2-ones by Microwave-Assisted Radical Cyclization. Synlett. 2004;6:1049-1053.

Kuramoto Y et al. A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group. J Med Chem. 2003; 46(10): 1905-17.

金田幸, 梶村芳雄. 新規抗真菌抗生物質BacillopeptinsおよびFusaricidinsについて. 薬学雑誌. 2002; 122(9): 651-671.

Akamatsu H et al. New efficient route for solid phase synthesis of benzimidazole derivatives. J Comb Chem. 2002; 4(5): 475-83.

Akamatsu H et al. Reactivity switching on solid support: solid-phase synthesis of tertiary amines by reduction of tertiary amides with LiAlH4. Tetrahedron Lett. 2002; 43: 8867-9.

Nakaizumi A et al. Frequent multiple c-Ki-ras oncogene activation in pancreatic juice from patients with benign small pancreatic cysts. Digestive Endoscopy. 2001;13( 2): 77-81.

Tanaka T et al. Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J Lipid Res. 2001;42(5): 751-9.

Maeda S et al. Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay. J Clin Microbiol. 2000;38(1): 210-4.

Takai S et al. Characterization of recombinant human chymase expressed in Escherichia coli. Jpn J Pharmacol. 2000; 82(2): 144-9.

Yoshimatsu T et al. Improvement of retroviral packaging cell lines by introducing the polyomavirus early region. Hum Gene Ther. 1998; 9: 161-72.

Nagao Y et al. Intramolecular nonbonded S･･･O interaction recognized in (acylimino)thiadiazoline derivatives as angiotensin II receptor antagonists and related compounds. J Am Chem Soc. 1998; 120: 3104-10.

Tamura K et al. Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist. J Cardiovasc Pharmacol. 1997; 30(5): 607-15.

Tamura K et al. In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist. Biol Pharm Bull. 1997; 20(8): 850-5.

Hirata T et al. Quantitative structure-activity relationships of benzoyliminothiadiazoline derivatives as andiotensin II receptor antagonists. Bioorg Med Chem Lett. 1997; 7(4): 385-8.

Hirata T et al. A facile synthesis of 2-acylimino-3-biphenylmethyl-1,3,4-thiasiazoline derivatives. Heterocycles. 1997; 44(1): 133-8.

Kikuchi A et al. Efficient gene transfer to EGF receptor overexpressing cancer cells by means of EGF-labeled cationic liposomes. Biochem Biophys Res Commun. 1996; 227(3): 666-71.

Huang TH et al. Repression by a differentiation-specific factor of the human cytomegalovirus enhancer. Nucleic Acids Res. 1996;24(9):1695-701.

Hirata T et al. Acyliminothiadiazoline derivatives: New, highly potent, and orally active angiotensin II receptor antagonists. Bioorg Med Chem. 1996; 6(13): 1469-74.

生方公子ほか. ペニシリン耐性肺炎球菌の臨床分離株における薬剤耐性機構について ペニシリン結合蛋白とPBP2B遺伝子の解析. 日本化学療法学会雑誌. 1994;42(11): 1225-35.

Murakami T et al. Dose-dependent plasma clearance of human epidermal growth factor in rats. J Pharm Sci. 1994;83(10):1400-3.

Kyo E et al. Reduced tumorigenicity and cell motility of a gastric-carcinoma cell-line by introduction of wild-type p53 gene. Int J Oncol. 1993;3(2):265-71.

Kiyohara Y et al. Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds. Biol Pharm Bull. 1993;16(1):73-6.

Murakami T et al. Effect of absorption promoters on subcutaneous absorption of human epidermal growth factor in rats. J Pharm Sci. 1993;82(3):236-9.

Yokozaki H et al. Biologic effect of human hepatocyte growth-factor on human gastric-carcinoma cell-lines. Int J Oncol. 1993; 3(1): 89-93.

清水信行ほか. ブレオマイシンを封入したEGF修飾リポソームの受容体を介した殺細胞効果. Drug Deliv Syst. 1993; 8(3): 193-7.

Kitadai Y et al. GC factor represses transcription of several growth factor/receptor genes and causes growth inhibition of human gastric carcinoma cell lines. Cell Growth Differ. 1993; 4(4): 291-6.

Ito R et al. Interleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res. 1993; 53(17): 4102-6.

Okuhira M et al. Beta-blocking action of bopindolol, a new beta-blocker, and its active metabolite in open chest dogs. Arch Int Pharmacodyn Ther. 1993; 323:5-15.

Koide H et al. Recognition of an antiparallel beta-sheet structure of human epidermal growth factor by its receptor. Site-directed mutagenesis studies of Ala-30 and Asn-32. FEBS Lett. 1992; 302(1): 39-42.

Koide H et al. A site-detected mutagenesis study on the role of isoleucine-23 of human epidermal growth factor in the receptor binding. Biochim Biophys Acta. 1992; 1120(3): 257-61.

Ubukata K et al. Rapid detection of the mecA gene in methicillin-resistant Staphylococci by enzyme detection polymerase chain reaction products. J Clin Microbiol. 1992 Jul;30(7):1728-33.

Kato Y et al. Existence of two pathways for the endocytosis of epidermal growth factor by rat liver: phenylarsine oxide-sensitive and -insensitive pathways. Proc Natl Acad Sci U S A. 1992; 89(18): 8507-11.

Ito M et al. Growth inhibition of transforming growth factor beta on human gastric carcinoma cells: receptor and postreceptor signaling. Cancer Res. 1992; 52(2): 295-300.

Shioi A et al. Interleukin 4 inhibits murine osteoclast formation in vitro. J Cell Biochem. 1991; 47(3): 272-7.

Suzuki H et al. Gene mapping of mouse IL-4 receptor: the loci of interleukin 4 (IL-4) receptor gene and lymphocyte function associated antigen 1 (LFA-1) gene are closely linked on chromosome 7. Immunogenetics. 1991; 34(4): 252-6.

Kyo E. Inhibition of 3H-TdR uptake for human gastric carcinoma cells by epidermal growth factor specific antibody. Hiroshima J Med Sci. 1991; 40(1): 15-21.

坂本俊治. 細胞増殖の制御 遺伝子工学による増殖因子の産生と基礎研究・臨床応用への可能性. 蛋白質 核酸 酵素. 1991; 36(7): 1107-13.

Kiyohara et al. Improvement in wound healing by epidermal growth factor (EGF) ointment. II. Effect of protease inhibitor, nafamostat, on stabilization and efficacy of EGF in burn. J Pharmacobiodyn. 1991; 14(1): 47-52.

Kajikawa K et al. Expression of epidermal growth factor in human tissues. Immunohistochemical and biochemical analysis. Virchows Arch A Pathol Anat Histopathol. 1991; 418(1): 27-32.

Takekura N et al. Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells. Int J Cancer. 1991 1; 47(6): 938-42.

MurakamiT et al. Enhanced rectal and nasal absorption of human epidermal growth factor by combined use of the absorption promoter and the synthetic polymer in rats. Eur J Drug Metab Pharmacokinet. 1991; Spec No 3: 125-31.

Yanai S et al. Kinetic analysis of receptor-mediated endocytosis of epidermal growth factor by isolated rat hepatocytes. Am J Physiol. 1991; 260(3 Pt 1): C457-67.

Hatono S et al. Absorption, biliary excretion, and metabolism of a new cholelitholytic agent, ursodeoxycholyl N-carboxymethylglycine and its esters in rats. J Pharmacobiodyn. 1991; 14(10): 561-6.

Ito M et al. Expression of several growth factors and their receptor genes in human colon. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990; 59(3): 173-8.

Okumura K et al. Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF. Pharm Res. 1990; 7(12): 1289-93.

Amagase H et al. Possible mechanism of gastric mucosal protection by epidermal growth factor in rats. Life Sci. 1990; 47(14): 1203-11.

Amagase H et al. Protective effect of human epidermal growth factor against the experimental gastric mucosal lesions in rats. Life Sci. 1990; 47(12): 1031-6.

Yoshida K et al. EGF and TGF-alpha, the ligands of hyperproduced EGFR in human esophageal. Int J Cancer. 1990 15; 45(1): 131-5.

Amagase H et al. Epidermal growth factor prolongs survival time of tumor-bearing mice. Jpn J Cancer Res. 1990; 81(5): 495-500.

Yoshida K et al. Expression of epidermal growth factor, transforming growth factor-alpha and their receptor genes in human gastric carcinomas; implication for autocrine growth. Jpn J Cancer Res. 1990; 81(1): 43-51.

Amagase H et al. Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice. J Pharmacobiodyn. 1990; 13(4): 263-8.

Sagara Y et al. Structual organization of the bovine adrenodoxin gene. J Biochem. 1990; 107(1): 77-83.

Cooke RM et al. Nuclear-magnetic-resonance studies of human epidermal growth factor. Eur J Biochem. 1990; 193(3): 807-15.

Sato H et al. Internalization of EGF in perfused rat liver is independent of the degree of receptor occupancy. Am J Physiol. 1990; 258(5 Pt 1): G682-9.

Yanai S et al. Kinetic analysis of the downregulation of epidermal growth factor receptors in rats in vivo. Am J Physiol. 1990; 258(4 Pt 1): C593-8.

Ohshita Y et al. A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem Biophys Res Commun. 1990; 172(3): 1028-34.

Yoshida K et al. Epidermal growth factor induces the expression of its receptor gene in human gastric carcinoma cell line TMK-1. Jpn J Cancer Res. 1989; 80(8): 743-6.

Kim DC et al. Kinetic analysis of the elimination process of human epidermal growth factor (hEGF) in rats. Biochem Pharmacol. 1989 15; 38(2): 241-9.

Sato H et al. Decrease in the number of receptors for epidermal growth factor in the liver of D-galactosamine-intoxicated rats. Biochem Pharmacol. 1989 15;38(16): 2663-71.

Murakami T et al. Down-regulation and its effect of epidermal growth factor receptors on the pharmacokinetics of human epidermal growth factor after I.v. administration in rats. Int J Pharmaceutics. 1989; 54: 259-67.

Ishii Y et al. Preparation of EGF labeled liposomes and their uptake by hepatocytes. Biochem Biophys Res Commun. 1989 28; 160(2): 732-6.

Hayashi T et al. A sensitive enzyme immunoassay for human epidermal growth factor. Determination of hEGF in human serum and urine and pharmacokinetics in mouse. J Pharmacobiodyn. 1989; 12(7): 410-5.

Amagase H et al. Epidermal growth factor receptor-mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors. Jpn J Cancer Res. 1989; 80(7): 670-8.

Kohda D et al. Polypeptide chain fold of human transforming growth factor alpha analogous to those of mouse and human epidermal growth factors as studied by two-dimensional 1H NMR. Biochemistry. 1989; 28(3): 953-8.

Hayashi T, Sakamoto S. HPLC analysis of human epidermal growth factor using immunoaffinity precolumn. II. Determination of hEGF in biological fluids. Chromatographia. 1989; 27(11): 574-80.

Hayashi T, Sakamoto S. HPLC analysis of human epidermal growth factor using immunoaffinity precolumn. I. Optimization of immunoaffinity column. Chromatographia. 1989; 27(11): 569-73.

Murakami T et al. Biliary and urinary excretions of immunoreactive human epidermal growth factor after intravenous administration in rats. Int J Phamaceutics. 1989; 49: 173-8.

Imanishi K et al. Inhibition of growth of human lung adenocarcinoma cell lines by anti-transforming growth factor-alpha monoclonal antibody. J Natl Cancer Inst. 1989; 81(3): 220-3.

Misoka F et al. Overproduction of huma insulin-like growth factor-II in Escherichia coli. Biotechnol Lett. 1989; 11(12): 839-44.

Araki F et al. Stability of recombinant human epidermal growth factor in various solutions. Chem Pharm Bull. 1989; 37(2): 404-6.

鳩野俊三ほか. 胆汁酸をキャリアとした新規制癌剤CA102 Drug Delivery System. 1989; 3(3): 445-9.

Sato H et al. Dynamic determination of kinetic parameters for the interaction between polypeptide hormones and cell-surface receptors in the perfused rat liver by the multiple-indicator dilution method. Proc Natl Acad Sci U S A. 1988; 85(21): 8355-9.

Fujiki H et al. Diarrhetic shellfish toxin, dinophysistoxin-1, is a potent tumor promoter on mouse skin. Jpn J Cancer Res. 1988; 79(10): 1089-93.

Murakami T et al. Intravenous and subcutaneous pharmacokinetics and rectal bioavailability of human epidermal growth factor in the presence of absorption promoter in rat. Int J Pharmaceutics. 1988; 46: 9-17.

Koide H et al. Biosynthesis of a protein containing a nonprotein amino acid by Escherichia coli: L-2-aminohexanoic acid at position 21 in human epidermal growth factor. Proc Natl Acad Sci U S A. 1988; 85(17): 6237-41.

Hayashi T et al. Determination of epidermal growth factors in human urine by high performance liquid chromatography using anti-hEGF antibody precolumn. Anal Sci. 1988; 4: 313-6.

Hayashi T et al. Radioimmunoassay of human epidermal growth factor--hEGF levels in human body fluids. J Pharmacobiodyn. 1988; 11(3): 146-51.

Kim DC et al. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci. 1988; 77(3): 200-7.

Yachi K et al. Comparison of specific binding of human epidermal growth factor (EGF) to sinusoidal and bile canalicular membranes isolated from rat liver. J Biochem. 1988; 103(3): 448-51.

Yasui W et al. Interaction between epidermal growth factor and gastrin on DNA synthesis of the gastrointestinal mucosa in rats. Hiroshima J Med Sci. 1988; 37(1): 1-6.

Yasui W et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988; 48(1): 137-41.

Noda Y et al. Immunohistochemical localization by monoclonal antibody of human epidermal growth factor in mixed tumors of the skin. J Cutan Pathol. 1987 Dec;14(6):337-42.

Mori M et al. Immunohistochemical distribution of human epidermal growth factor in salivary gland tumors. Virchows Archiv A. 1987; 411(6): 499-507.

Oda N et al. Purification and characterization of phospholipase A2 from Trimeresurus gramineus Venom. J Biochem. 1987; 102(6): 1441-9.

Makino K et al. Proton nuclear magnetic resonance study on the solution conformation of human epidermal growth factor. Proc Natl Acad Sci U S A. 1987 Nov;84(22):7841-5.

Imada O et al. Long-latency growth-promoting activity of EGF when administered to mice at the neonatal stage. Am J Physiol. 1987; 253(3 Pt 1): E251-4.

Tsukitani K et al. Immunohistochemical detection of human epidermal growth factor in submandubular glands and their tumors using a polyclonal antiserum and monoclonal antibody. Histochemistry. 1987; 87(4): 293-300.

Yoshida S et al. Effect of biosynthetic human epidermal growth factor on the synthesis and secretion of mucin glycoprotein from primary culture of rabbit fundal mucosa cells. In Vitro Cell Dev Biol. 1987; 23(7): 460-4.

Tsukumo K et al. Purification and characterization of high molecula weight human epidermal growth factor from human urine. Biochem Biophys Res Commun. 1987; 145(1): 126-33.

Ohshita Y, Hozumi T. Sequence of the rat β-globin mRNA. Nucleic Acids Res. 1987; 15(3):1336.

柳井薫雄ほか. ラット遊離肝細胞を用いたヒト上皮細胞増殖因子とその受容体の相互作用の速度論的解析. 薬物動態. 1987; 2(4): 368-369.

佐藤博章ほか. 上皮成長因子(EGF)受容体の肝細胞表面における挙動‐肝灌流法を用いた速度論的解析. 薬物動態. 1987; 2(4): 366-367.

Yanai S et al. Binding of human epidermal growth factor to tissue homogenates of the rat. Chem Pharm Bull. 1987; 35(12): 4891-7.

Yasui W et al. Expression of Ha-ras oncogene product in rat gastrointestinal carcinomas induced by chemical carcinogens. Acta Pathol Jpn. 1987;37(11): 1731-41.

林奉権ほか. 自動試料前処理装置を用いる血しょう中のアドリアマイシン及びその代謝産物の高速液体クロマトグラフィーによる定量. 分析化学. 1986; 35: 230-5.

金東出ほか. ヒト上皮細胞増殖因子(EGF)のラットにおける体内動態の速度論的解析. 薬物動態. 1986; (3):256-257.

Yasui W et al. Gut endocrine cells in rat stomach carcinoma induced by N-methyl-N'-nitro-N-nitrosoguanidine. J Cancer Res Clin Oncol. 1986; 111(2): 87-92.

Yasui W et al. Cholecystokinin inhibition of tumor growth and gastrin-stimulated cyclic adenosine 3':5'-monophosphate metabolism in human gastric carcinoma in nude mice. Cancer Res. 1986; 46(2): 740-3.

Akiyama H et al. Carcinoembryonic antigen (CEA) in gallbladder bile and mucosa in cholecystolithiasis. Acta Chir Scand. 1986;152:509-13.

Yatsunami T et al. Synthesis and antibacterial of sarcotoxin ia and its analogs, a bacterial protein from haemolyph of Sarcophaga perigrina LARVE. Peptide Chem. 1986; 158-62.

Arakawa M et al. Further characterization of the inhibition of casein production in a primary mouse mammary epithelial cell culture by epidermal growth factor. Antagonism by cyclic AMP. Exp Cell Res. 1985;158(1):111-8.

Miyake T et al. Secretion of human interferon-alpha induced by using secretion vectors containing a promoter and signal sequence of alkaline phosphatase gene of Escherichia coli. J Biochem. 1985; 97(5): 1429-36.

Nakagawa S et al. Biological effects of biosynthetic human EGF on the growth of mammalian cells in vitro. Differentiation. 1985; 29(3): 284-8.

Yasui W et al. Calcium-activated, phospholipid-dependent protein kinase in human gastric mucosa and carcinoma. Jpn J Cancer Res. 1985; 76(12): 1168-73.

Ochiai A et al. A monoclonal antibody reacting with various human carcinomas and fetal colon and esophagus. Jpn J Cancer Res. 1985; 76(10): 915-8.

Yasui W et al. Type I and II cyclic adenosine 3':5'-monophosphate-dependent protein kinase in human gastric mucosa and carcinomas. Cancer Res. 1985; 45(4): 1565-8.

Ohnishi M et al. Water-soluble carrier proteins having carboxyl spacer group. Chem Pharm Bull. 1985; 33(7): 2871-6.

Ohishi M et al. Heterobifunctional reagents for cross-linking of sugar with protein. Chem Pharm Bull. 1985; 33(2): 674-8.

Sumi S et al. Overproduction of a gastrointestinal hormone, secretin, in Escherichia coli cells and its chemical characterization. Gene. 1984; 29(1-2): 125-34.

鳩野俊三ほか. 胆汁酸の代謝（第14報）サルコシン抱合胆汁酸. 薬学雑誌. 1984; 104(5): 466-71.

Kimura M et al. Synthesis, intestinal absorption and metabolism of sarcosine conjugated ursodeoxycholic acid. Steroids. 1984; 43(6): 677-87.

Tachiki T et al. Glutamine production in high concentrations with energy transfer employing glutamine synthetase from Micrococcus glutamicus. J Gen Appl Microbiol. 1983; 29: 355-63.

Tachiki T et al. Purification and some properties of glutamate synthase from Gluconobacter suboxydans growth on glutamate as a nitrogen source. J Ferment Technol. 1983; 61(2): 179-84.

Yazaki A, Ohno S. Simple construction of human c-myc gene implicated in B-cell neoplasmas and its relationship with avian v-myc and human lympholines. Scand J Immunol. 1983; 18: 373-88.

Yazaki A, Ohno S. Recurrence of 49-base decamers, nonomers, and octamers within mouse C mu gene of Ig heavy chain and its primordial building block. Proc Natl Acad Sci U S A. 1983; 80(8): 2337-2340.

Otsuka E et al. A new synthetic method for 5'-triphosphoryl-adenylyl-(2'-5')-adenylyl-(2'-5')-adenosine (2-5A) and 2-5A core using 3'-o-tetrahydrofuranyl-adenosine derivatives. Chem Pharm Bull. 1981; 30(1): 376-8.

Tabushi I, Yazaki A. P-450 type dioxygen activation using H2/colloidal Pt as an effective donor. J Am Chem Soc. 1981; 103: 7371-3.

Tabushi I, Yazaki A. N-alkyl-4,4'-bipyridyl. A new efficient electron carrire in the photochemical hydrogen producing system. Tetrahedron. 1981; 37(24): 4185-8.

Tabushi I, Yazaki A. Effective hydrogen generation system by use of ascorbic acid as a reversible electron donor. J Org Chem. 1981; 46: 1899-901.

Arakawa M et al. Tissue distribution and metabolism of drugs V: Effect of secretin and pancreozymin on drug transport in rabbit pancreas. J Pharm Sci. 1980; 69(1): 27-30.